Migraine Prevention is Personal to Us

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies.

Alder was founded in 2004 with a shared vision to go beyond the norm in designing antibodies that were focused on the unmet medical needs of patients. We see our company as a compassionate catalyst for change.

One of our founders, John Latham, our Chief Scientific Officer, has a deep personal drive to find a solution for migraines. His wife, Nanette, has suffered from migraines for more than 40 years. “In college,” he says, “I never understood why she missed classes at least a day a week. And it got progressively worse from there.” When John realized that he could design a drug that he believed would relieve her suffering, there was no turning back.

Migraine prevention therapies did exist; however they sometimes took weeks or months to work, if they worked at all, and patients often experienced burdensome side effects such as memory problems, drowsiness, and/or weight gain.1,2 Given these treatment limitations, the team at Alder sought to develop a drug specifically designed to meet the need of patients with migraine – an efficacious, rapidly acting and well-tolerated treatment option.

We Understand Migraine

At Alder, we know the physical and emotional toll migraine can take, and in fact, some of our employees experience it themselves. We have leveraged our monoclonal antibody (mAb) expertise to design Eptinezumab, our pivotal-stage mAb that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention.

1Bigal ME, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009:49(7):1028-1041.

2Hepp, Z, Bloudek LM, Varon SF. Systematic Review of Migraine Prophylaxis Adherence and Persistence. J. Manag Care Pharm. 2014 Jan;20(1):22-33.